Polivy market seen topping $5 billion by 2030

The Business Research Company says the Polivy market will exceed $5 billion in 2030, driven by wider use in diffuse large B-cell lymphoma and growing demand for antibody-drug conjugate therapies. North America and the U.S. are forecast to lead the market, while previously untreated diffuse large B-cell lymphoma remains the biggest segment.

Why it matters: - Polivy is part of a fast-growing oncology niche that the report values at more than $5 billion by 2030. - The forecast suggests strong demand for targeted lymphoma therapies as cancer care shifts toward precision medicine and antibody-drug conjugates. - The market's growth could affect treatment choices, reimbursement priorities, and oncology infrastructure planning in major health systems.

What happened: - The Business Research Company released a 2026 Polivy market report covering global size, trends, segments, and forecasts through 2035. - The report estimates the Polivy market will surpass $5 billion in 2030. - The report projects a 22% CAGR for the market leading up to 2030. - The report says North America will be the largest region in 2030, at $2.23 billion. - The report says the U.S. will be the largest country in 2030, at $1.99 billion. - The report identifies previously untreated diffuse large B-cell lymphoma as the largest segment by indication in 2030, at 52% of the market, or $2 billion. - The report also segments the market by dosage form into injectable solution and by distribution channel into direct sales, pharmaceutical wholesalers, and online pharmacies. - The company offered a free sample of the report and a full report.

The details: - North America is forecast to grow from $0.85 billion in 2025 to $2.23 billion in 2030, at a 21% CAGR. - The U.S. is forecast to grow from $0.78 billion in 2025 to $1.99 billion in 2030, also at a 21% CAGR. - The previously untreated diffuse large B-cell lymphoma segment is expected to grow because of earlier-line targeted treatment use, stronger focus on first-treatment response outcomes, broader use of novel biologics, increased physician adoption of combination therapies, and evidence supporting better disease control. - The report says the relapsed or refractory diffuse large B-cell lymphoma segment is the other major indication category. - The report says the Polivy market represents about 1% of the oncology drugs parent market, which is expected to reach about $441 billion by 2030. - The report says the market is nearly 0.2% of the broader pharmaceuticals industry, projected at $2,496 billion by 2030. - The report says growth is being driven by expansion of indications, rising global incidence of hematological malignancies, and increasing preference for antibody-drug conjugate therapies. - The report estimates those drivers contribute about 2.6%, 2.4%, and 2.2% annual growth, respectively. - The previously untreated diffuse large B-cell lymphoma and relapsed or refractory diffuse large B-cell lymphoma segments are projected to add more than $3 billion in combined market value by 2030. - The report says the previously untreated segment will grow by $2 billion over the next five years, while the relapsed or refractory segment will grow by $1 billion. - The 2026 report adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies and future trends, and updated graphics and tables. - The Business Research Company says it has published more than 30,000 reports across 27 industries and 60 geographies, using 1,500,000 datasets, secondary research, and interviews with industry leaders.

Between the lines: - The forecast points to a market concentrated in the U.S. and other advanced care systems with stronger access to specialty oncology treatment. - The emphasis on first-line diffuse large B-cell lymphoma suggests the biggest commercial upside may come from earlier use, not only later-stage rescue treatment. - The report's growth drivers track with a broader oncology trend toward precision therapies that aim to improve outcomes while narrowing systemic exposure.

What's next: - The report expects North America and the U.S. to keep leading the market through 2030. - The biggest growth opportunity appears to be the previously untreated diffuse large B-cell lymphoma segment, followed by relapsed or refractory disease. - Broader clinical adoption of antibody-drug conjugates will likely remain a key watchpoint for the market's pace of expansion.